On Sept. 27, the first two subjects enrolled in our new ibogaine study at Pangaea Biomedics, a treatment facility in Playas de Tijuana, Mexico. It is led by Principal Investigator Valerie Mojeiko and co-investigator Thomas Kingsley Brown, Ph.D. The researchers are collecting data from opiate-dependent subjects for one year after ibogaine-assisted detoxification to evaluate the long-term outcomes of ibogaine treatment. Brown met with both subjects and administered the Subjective Opiate Withdrawal Scale and the Addiction Severity Index (ASI). Both subjects are happy to participate, Brown said. One subject had difficulty answering all of the ASI questions because of withdrawal symptoms, so the interview was finished by phone Sept. 29. “It feels great to have the first two subjects enrolled and to be doing this work,” Brown said. The entire study will enroll 30 subjects and follow them for a year after treatment.